Takhzyro market outlook brightens on HAE growth

The Business Research Company says the global Takhzyro market is set for stronger growth through 2030 as hereditary angioedema diagnosis expands and healthcare spending rises. North America led in 2025, while Asia-Pacific is expected to grow fastest as rare-disease detection and care capacity improve.

Why it matters: - Takhzyro’s market outlook is tied to the broader rise in hereditary angioedema diagnosis and treatment demand. - Growth in rare-disease care, healthcare infrastructure and reimbursement support could expand access to long-term preventive therapy. - The market also reflects a shift toward patient-friendly biologics and self-administered treatments for chronic rare diseases.

What happened: - The Business Research Company published a 2026 outlook saying the Takhzyro market is improving on growing global demand. - The report covers historical performance, drivers, regional trends and forecast themes for 2026 to 2030. - Takhzyro, or lanadelumab-flyo, is a prescription monoclonal antibody used to prevent hereditary angioedema attacks in patients aged 2 years and older. - The drug blocks plasma kallikrein, lowering bradykinin and helping reduce the frequency and severity of swelling episodes. - North America held the largest Takhzyro market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - The market’s prior growth was linked to better detection of hereditary angioedema cases, targeted kallikrein inhibitors, more specialty care facilities, rising rare-disease awareness and supportive orphan-drug reimbursement policies. - The forecast period is expected to benefit from higher investment in rare-disease treatments, broader use of personalized medicine, stronger prevention-focused care and advances in monoclonal antibody technology. - Key trends expected in the market include longer-acting prophylactic therapies, more monoclonal antibody use in rare conditions, more self-administered injectable options, preventive HAE management and better patient compliance through extended dosing schedules. - Hereditary angioedema is a rare genetic disease that can cause recurrent swelling and can become life-threatening when it affects the airway. - A January 2025 PubMed study cited in the release reported a pooled U.S. prevalence of 1.22 cases per 100,000 people, with HAE type 1 the most common and slightly more prevalent among females. - Global healthcare spending is rising, and OECD member countries allocated about 9.3% of GDP to health in 2024, according to a November 2025 report. - The report says broader healthcare budgets can lift demand for innovative treatments and affect pricing and cost-effectiveness assessments. - Other regions covered in the analysis include Western Europe, Eastern Europe, South America, the Middle East and Africa. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The release includes links for a free sample and the full report: Download a free sample of the Takhzyro market report and View the full Takhzyro market report.

Between the lines: - The report points to a market supported by both more diagnosed patients and longer-term treatment adoption, not just by overall drug demand. - Asia-Pacific’s expected outperformance suggests that diagnosis rates and healthcare investment may be becoming more important than current market maturity. - The emphasis on prophylaxis and self-injection signals a preference for convenience and chronic management over reactive treatment.

What's next: - The Business Research Company expects the Takhzyro market to benefit through 2030 from rare-disease investment, better diagnosis and wider use of preventive biologics. - Future market performance will likely hinge on how quickly healthcare systems expand rare-disease infrastructure and reimbursement access. - The company also highlighted upcoming report tools aimed at helping buyers assess market attractiveness, TAM and competitive positioning.

The bottom line: - Takhzyro’s market story is increasingly about global rare-disease detection, preventive care and healthcare spending growth, with the strongest momentum likely to come from emerging markets and longer-acting treatment options.